Immix Biopharma Inc (IMMX) Stock Analysis

$8.690

-0.526 (-6.05%)At close

Loading chart…

High: 9.290
Open: 9.100
VWAP: 8.88
Volume: 1.48M
Mkt Cap: 56.26M
Low: 8.660
Amount: 13.17M
EV/EBITDA, TTM: 0.00

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The Company's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.

immixbio.com

AI analysis of Immix Biopharma Inc (IMMX)

Buy

Immix Biopharma Inc is a good buy right now due to its promising clinical trial results for NXC-201, which showed an 89% complete response rate, and a significant price target increase from analysts, with BofA setting it at $30, indicating over 190% upside potential from the current price of $9.46. However, the stock has experienced a 22.08% decline over the last 20 days, which presents a risk to consider.

Valuation Metrics

The current forward P/E ratio for Immix Biopharma Inc (IMMX) is 0.00, compared to its 5-year average forward P/E of -3.84.

Forward P/E

Overvalued

5Y Average P/E

-3.84

Current P/E

0.00

Overvalued

-1.86

Undervalued

-5.83

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-2.48

Current EV/EBITDA

0.00

Overvalued

0.03

Undervalued

-5.00

Forward P/S

Fair

5Y Average P/S

7.80

Current P/S

27.53

Overvalued

29.76

Undervalued

-14.16

Alphio AI Price Scenarios for IMMX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

Bull

Bull · 25%IMMX

$3.24

Scenario price

Base

Base · 50%IMMX

$2.79

Scenario price

Bear

Bear · 25%IMMX

$2.22

Scenario price

Whales holding IMMX

Logos Global Management, L.P.

+ HoldingIMMX

-13.69%

3M Return

Deep Track Capital, LP

+ HoldingIMMX

-28.29%

3M Return

Events Timeline

2026-09-29 (ET)